Dyslipidemia frequency in patients with plaque psoriasis: A cross-sectional study
Keywords:
Psoriasis, dyslipidemia, scaly plaquesAbstract
Background: Psoriasis is a disorder of the skin that is non-contagious and has a long duration. It affects 1- 3% of the population. Psoriasis is a chronic disorder of the skin and associated with dyslipidemia.
Objective: The aim of this study was to find out the frequency of dyslipidemia in individuals with plaque psoriasis
Materials and method: The present cross-sectional study was conducted at the dermatology department Naseer ullah Khan Babar memorial hospital, Peshawar from January 2025 to June 2025 after taking approval from the research committee of the hospital. Non probability sampling method was used and sample size was determined through WHO calculator. The size of the sample was 106 using 95% confidence level and 7% margin of error. Individuals of both genders and different age groups (ranged 15-65) years with chronic plaque psoriasis were included. SPSS Version 24 was used for data analysis.
Results: A total of 106 individuals were enrolled in this study out of which 63 were males and 43 were females. The mean age of the study population was 38.77 with standard deviation 12.11(ranged 18-65) years. The participants were classified in to two age groups < 15-40 years and above 40 to 65 years. Based on the duration of the illness, individuals were divided into two groups. Those who have had the illness for less than ten years, whereas the other group has had it for more than ten years. The mean duration was 8.52±6.2 standard deviations, with a minimum of one year and a maximum of twenty-five years. Dyslipidemia was found in 36 (34%) of the selected individuals in the whole sample. It was found that 24% of patients had increased total cholesterol, 10% had higher triglycerides, 4% had greater low density lipoproteins, and 21% had elevated high density lipoproteins. There were 16 individuals with dyslipidemia in the 15–40 age group and 20 individuals in the 40–65 age group, with a substantial P-Value of less than 0.001. Dyslipidemia was discovered in 16 patients in the disease duration group under 10 years and in 20 patients in the duration group over 10 years, with a significant P Value less than 0.001.
Conclusion: The present study concluded that dyslipidemia was most prevalent (34%) in individuals with plaque psoriasis and its frequency increased with the duration of the disease
Downloads
References
Jamil A, Ahsan U, Malik LM, Azfar NA, Jahangir M. Frequency of dyslipidemia in patients with psoriasis. J Pak Assoc Dermatol 2014; 24(4): 307-11.
. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investigative Dermatol 2013;133(2):377-85.
. Mahajan R, Handa S. Pathophysiology of psoriasis. Indian J Dermatol Venereol Leprol 2013;79(7):1-9.
. Mawla MA, Abulmajd Y, Soliman M, Amer A, Nasr M, Victor O. Serum Interleukin (IL)-17 in Psoriasis. J Am Sci 2013;9(12):229-32.
. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006;24(5):438-47.
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Assoc Dermatol 2009;59(8):512.
. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145(6):700-3.
. Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006;6(1):48-53.
. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus:
.Gibson LE, Perry HO. Papulosquamous eruptions and exfoliative dermatitis. In: Moschella SL, Hurley HJ, editors. Dermatology. Philadelphia: WB Saunders, 2017.p.607-51
.Ortonne JP. Psoriasis, metabolic syndrome and its components. Ann Dermatol Venereal. 2008;135:235-42.
. Ayala F. Clinical aspects and comorbidities of psoriasis. J Rheumatol. 2009;83:19-20
.Gelfland JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
. Gisondi P, Girolomoni G. Cardio metabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr. 2009;2:14-21.
. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373-7.
. Velageleti RS, Massaro J, Vasan RS, Robin SJ, Kannel WB, Levy D. Relation of lipid concentrations to heart failure incidence: The Framingham heart study. Circulation. 2009;120:2345-51
.Khan NI, Naz L, Mushtaq S, Rukh L, Ali S, Hussain Z. Ischemic stroke: Prevalence of modifiable risk factors in male and female patients in Pakistan. Pak J Pharm Sci. 2009;22:62-7
Malone DC. Association of cardio metabolic risk factors and prevalent cardiovascular Events. Metabolic Syndr Relat Disord. 2009; 7:585-93
.Richardson SK, Gelfland JM. Update on the natural history and systemic treatment of psoriasis. Advances in Dermatology. 2008;24:171-96
.Owen CM, Chalmers RJG, Sullivan TO, Griffiths CEM.A systemic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol.2000;143:15-24
.Zelickson BD, Muller SA. Generalized pustular psoriasis: a review of 63 cases. Arch Dermatol 1991; 127:1339–45
.Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption. Arch Dermatol. 2016; 135:1479-84..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
